CD274 and non-small cell lung carcinoma: Recently, immune checkpoint blockade (ICB) targeting PD-L1/PD-1 blocking therapy has achieved some success in many malignancies including non-small-cell lung cancer (NSCLC) and melanoma (Punekar et al. 2022; Jacquelot et al. 2017).